ANN ONCOL:接受niraparib治疗患者的安全性及剂量调整

2018-08-26 MedSci MedSci原创

niraparib是多聚合酶抑制剂,主要用于接受铂类化疗后达到完全或部分缓解的复发上皮性卵巢癌,输卵管或原发腹膜癌患者的维持治疗。在ENGOT-OV16/NOVA试验中,由于治疗相关不良反应(TEAE)导致的药物减量率为68.9%,由于TEAE而中断治疗率为14.7%。ANN ONCOL近期发表了一篇文章,对该研究进行了回顾性分析以寻找可以预测药物减量的临床指标。

niraparib是多聚合酶抑制剂,主要用于接受铂类化疗后达到完全或部分缓解的复发上皮性卵巢癌,输卵管或原发腹膜癌患者的维持治疗。在ENGOT-OV16/NOVA试验中,由于治疗相关不良反应(TEAE)导致的药物减量率为68.9%,由于TEAE而中断治疗率为14.7%。ANN ONCOL近期发表了一篇文章,对该研究进行了回顾性分析以寻找可以预测药物减量的临床指标。

研究纳入的患者均接受了至少1个剂量的niraparib治疗。建立预测模型寻找可以预测在接受niraparib治疗30天内出现≥3级血小板减少的临床指标,并确定其界值。研究结果表明,在ENGOT-OV16/NOVA试验中,200mg是最常用的剂量。基线血小板数量和基线体重是出现≥3级血小板减少的危险因素。基线体重<77kg或基线血小板数量<150000/ul的患者事实上由于药物剂量降低而接受了平均200mg每天的药物剂量。剂量降低到200或100mg患者的无进展生存情况与一直接受初始300mg剂量治疗的患者一致。

文章最后认为,基线体重<77kg或基线血小板数量<150000/ul的患者接受初始剂量200mg/天具有临床获益。

原始出处:
J S Berek,U A Matulonis,et al.Safety and dose modification for patientw receiving niraparib.ANN ONCOL.August 2018 doi:https://doi.org/10.1093/annonc/mdy181

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865524, encodeId=8dc818655244d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 01 06:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338187, encodeId=6fb8133818eed, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Tue Aug 28 06:21:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581375, encodeId=391515813e5fc, content=<a href='/topic/show?id=8d991281805' target=_blank style='color:#2F92EE;'>#Niraparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12818, encryptionId=8d991281805, topicName=Niraparib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=855416780985, createdName=12498bb3m95(暂无昵称), createdTime=Tue Aug 28 06:21:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341136, encodeId=b97b3411364c, content=哈哈哈,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1ee1608797, createdName=huangshang9812, createdTime=Mon Aug 27 14:17:19 CST 2018, time=2018-08-27, status=1, ipAttribution=)]
    2018-11-01 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865524, encodeId=8dc818655244d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 01 06:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338187, encodeId=6fb8133818eed, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Tue Aug 28 06:21:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581375, encodeId=391515813e5fc, content=<a href='/topic/show?id=8d991281805' target=_blank style='color:#2F92EE;'>#Niraparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12818, encryptionId=8d991281805, topicName=Niraparib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=855416780985, createdName=12498bb3m95(暂无昵称), createdTime=Tue Aug 28 06:21:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341136, encodeId=b97b3411364c, content=哈哈哈,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1ee1608797, createdName=huangshang9812, createdTime=Mon Aug 27 14:17:19 CST 2018, time=2018-08-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865524, encodeId=8dc818655244d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 01 06:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338187, encodeId=6fb8133818eed, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Tue Aug 28 06:21:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581375, encodeId=391515813e5fc, content=<a href='/topic/show?id=8d991281805' target=_blank style='color:#2F92EE;'>#Niraparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12818, encryptionId=8d991281805, topicName=Niraparib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=855416780985, createdName=12498bb3m95(暂无昵称), createdTime=Tue Aug 28 06:21:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341136, encodeId=b97b3411364c, content=哈哈哈,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1ee1608797, createdName=huangshang9812, createdTime=Mon Aug 27 14:17:19 CST 2018, time=2018-08-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865524, encodeId=8dc818655244d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Nov 01 06:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338187, encodeId=6fb8133818eed, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Tue Aug 28 06:21:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581375, encodeId=391515813e5fc, content=<a href='/topic/show?id=8d991281805' target=_blank style='color:#2F92EE;'>#Niraparib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12818, encryptionId=8d991281805, topicName=Niraparib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=855416780985, createdName=12498bb3m95(暂无昵称), createdTime=Tue Aug 28 06:21:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341136, encodeId=b97b3411364c, content=哈哈哈,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e1ee1608797, createdName=huangshang9812, createdTime=Mon Aug 27 14:17:19 CST 2018, time=2018-08-27, status=1, ipAttribution=)]
    2018-08-27 huangshang9812

    哈哈哈,学习了

    0

相关资讯

NEJM:Niraparib可显著延长铂敏感的复发性卵巢癌患者无进展生存期

Niraparib是一种口服(腺苷二磷酸[ADP]核糖)聚合酶(PARP)1/2抑制剂,在卵巢癌患者中表现出临床活性。研究人员在该研究中试图评估niraparib vs 安慰剂对于铂类敏感、复发性卵巢癌患者的维持治疗效果。

FDA批准第三个PARPi卵巢癌新药niraparib

今日,TESARO迎来重磅喜讯——其PARP抑制剂niraparib (商品名ZEJULA)获得了美国FDA的批准上市,用于复发性上皮卵巢癌、输卵管癌或原发性腹膜癌女性患者的维持治疗。这些患者先前接受过铂类化疗,并出现完全响应或部分响应(complete or partial response)。

SGO 2018:Pembrolizumab联合Niraparib使卵巢癌患者获益

美国东部时间3月24日~27日,2018年美国妇科肿瘤学年会(SGO)在新奥尔良召开。丹娜法伯癌症研究院Panagiotis A. Konstantinopoulos报道了I/II期TOPACIO研究结果。TOPACIO研究初步结果显示,在铂类继发耐药或原发耐药的卵巢癌患者中,无论患者的生物标志物状态,PARP抑制剂niraparib联合抗PD-1单抗pembrolizumab治疗显示出疗效。

ESMO 2016:Niraparib可延长复发性卵巢癌患者的PFS

根据欧洲肿瘤医学学会大会上的3期数据显示,对于铂敏感的复发性卵巢癌女性患者,Niraparib维持治疗与安慰剂相比,可显著延长患者的无进展生存期(PFS)。 研究人员称:无论患者是否存在BRCA突变或同源重组缺陷状态,这种益处都存在。 先前发表的1期和2期临床试验结果表明:口服PARP抑制剂niraparib (Tesaro),对卵巢癌患者具有临床活性。 来自丹麦哥本哈根大学医院

Lancet Oncol:Niraparib治疗BRCA突变型散发肿瘤患者安全有效

ADP核糖聚合酶(PARP)在DNA修复和转录调节过程中起作用。Niraparib(MK4827)是一种口服的选择性PARP-1和PARP-2抑制剂,在缺乏BRCA和PTEN功能的基础肿瘤模型中可诱导致死性变化的产生。来自英国肿瘤研究结构的Shahneen K Sandhu等为了评估Niraparib的安全性、患者对治疗的耐受性、患者的最大耐受剂量、药代动力学和药效学特征,以及Niraparib的